South Korea
· Delayed Price · Currency is KRW HansBiomed Statistics
Total Valuation
HansBiomed has a market cap or net worth of KRW 121.17 billion. The enterprise value is 147.16 billion.
| Market Cap | 121.17B |
| Enterprise Value | 147.16B |
Important Dates
The next estimated earnings date is Thursday, December 19, 2024.
| Earnings Date | Dec 19, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
HansBiomed has 12.99 million shares outstanding. The number of shares has increased by 22.39% in one year.
| Shares Outstanding | 12.99M |
| Shares Change (YoY) | +22.39% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | 27.62% |
| Owned by Institutions (%) | 0.79% |
| Float | 6.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.46 |
| PB Ratio | 1.64 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 109.73, with an EV/FCF ratio of -180.97.
| EV / Earnings | -15.50 |
| EV / Sales | 1.82 |
| EV / EBITDA | 109.73 |
| EV / EBIT | n/a |
| EV / FCF | -180.97 |
Financial Position
The company has a current ratio of 1.10, with a Debt / Equity ratio of 0.45.
| Current Ratio | 1.10 |
| Quick Ratio | 0.45 |
| Debt / Equity | 0.45 |
| Debt / EBITDA | 11.25 |
| Debt / FCF | -41.47 |
| Interest Coverage | -1.00 |
Financial Efficiency
Return on equity (ROE) is -15.81% and return on invested capital (ROIC) is -1.40%.
| Return on Equity (ROE) | -15.81% |
| Return on Assets (ROA) | -1.16% |
| Return on Capital (ROIC) | -1.40% |
| Revenue Per Employee | 634.95M |
| Profits Per Employee | -74.75M |
| Employee Count | 127 |
| Asset Turnover | 0.64 |
| Inventory Turnover | 1.12 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.76% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -44.76% |
| 50-Day Moving Average | 10,167.20 |
| 200-Day Moving Average | 12,319.05 |
| Relative Strength Index (RSI) | 35.77 |
| Average Volume (20 Days) | 17,875 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HansBiomed had revenue of KRW 80.64 billion and -9.49 billion in losses. Loss per share was -752.85.
| Revenue | 80.64B |
| Gross Profit | 49.75B |
| Operating Income | -2.33B |
| Pretax Income | -8.82B |
| Net Income | -9.49B |
| EBITDA | 3.00B |
| EBIT | -2.33B |
| Loss Per Share | -752.85 |
Balance Sheet
The company has 8.02 billion in cash and 33.73 billion in debt, giving a net cash position of -25.70 billion or -1,979.07 per share.
| Cash & Cash Equivalents | 8.02B |
| Total Debt | 33.73B |
| Net Cash | -25.70B |
| Net Cash Per Share | -1,979.07 |
| Equity (Book Value) | 74.14B |
| Book Value Per Share | 5,686.06 |
| Working Capital | 4.58B |
Cash Flow
In the last 12 months, operating cash flow was 1.56 billion and capital expenditures -2.37 billion, giving a free cash flow of -813.21 million.
| Operating Cash Flow | 1.56B |
| Capital Expenditures | -2.37B |
| Free Cash Flow | -813.21M |
| FCF Per Share | -62.62 |
Margins
Gross margin is 61.70%, with operating and profit margins of -2.89% and -11.77%.
| Gross Margin | 61.70% |
| Operating Margin | -2.89% |
| Pretax Margin | -10.94% |
| Profit Margin | -11.77% |
| EBITDA Margin | 3.72% |
| EBIT Margin | -2.89% |
| FCF Margin | -1.01% |
Dividends & Yields
HansBiomed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.39% |
| Shareholder Yield | -22.39% |
| Earnings Yield | -8.07% |
| FCF Yield | -0.67% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HansBiomed has an Altman Z-Score of 2.89. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.89 |
| Piotroski F-Score | n/a |